Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

K Yamazaki,T Yamanaka,M Shiozawa,D Manaka,M Kotaka,M Gamoh,A Shiomi,A Makiyama,Y Munemoto,T Rikiyama,M Fukunaga,T Ueki,K Shitara, H Shinkai,N Tanida,E Oki,E Sunami, A Ohtsu, Y Maehara,T Yoshino

Annals of Oncology（2021）

引用 27|浏览83

暂无评分

摘要

•Oxaliplatin-based adjuvant chemotherapy is associated with PSN in patients with high-risk stage II colon cancer.•Three-month oxaliplatin-based adjuvant chemotherapy showed less grade ≥2 PSN than the 6-month regimen.•Three-month oxaliplatin-based adjuvant chemotherapy did not affect the 3-year DFS rate compared with the 6-month regimen.•A three-month course of adjuvant CAPOX can be an option for high-risk stage II colon cancer.

查看译文

关键词

high-risk stage II colon cancer,adjuvant chemotherapy,oxaliplatin,treatment duration

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要